Olema Pharmaceuticals Inc (OLMA)
$10.15
+0.15
(+1.5%)▲
Insights on Olema Pharmaceuticals Inc
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 247.4% return, outperforming this stock by 315.2%
Performance
- $9.92$10.20$10.15
2.27%
Downside
Day's Volatility :2.75%
Upside
0.49%
- $3.93$17.79$10.15
61.28%
Downside
52 Weeks Volatility :77.91%
Upside
42.95%
Returns
| Period | Olema Pharmaceuticals Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -12.97% | 2.0% | 0.0% |
6 Months | -12.89% | 11.7% | 0.0% |
1 Year | 145.1% | 5.8% | 1.3% |
3 Years | -67.75% | 14.2% | -22.1% |
Highlights
Market Capitalization | 551.9M |
Book Value | $4.62 |
Earnings Per Share (EPS) | -2.14 |
Wall Street Target Price | 24.75 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -26.64% |
Return On Equity TTM | -42.82% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -104.6M |
Diluted Eps TTM | -2.14 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.4 |
EPS Estimate Next Year | -2.66 |
EPS Estimate Current Quarter | -0.48 |
EPS Estimate Next Quarter | -0.51 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 143.84%
Technicals Summary
Sell
Neutral
Buy
Olema Pharmaceuticals Inc is currently in a neutral trading position according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Olema Pharmaceuticals Inc | -8.84% | -12.89% | 145.1% | -67.75% | -79.59% |
 Moderna, Inc. | -2.26% | 35.27% | -21.9% | -39.25% | 318.83% |
 Regeneron Pharmaceuticals, Inc. | -5.59% | 12.81% | 13.84% | 81.04% | 166.5% |
 Novo Nordisk A/s | -0.32% | 31.91% | 50.92% | 247.21% | 431.9% |
 Vertex Pharmaceuticals Incorporated | -2.67% | 11.53% | 21.99% | 86.62% | 131.89% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Olema Pharmaceuticals Inc | NA | NA | NA | -2.4 | -0.43 | -0.27 | NA | 4.62 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.9 | 25.9 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.09 | 47.09 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.76 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Olema Pharmaceuticals Inc | Buy | $551.9M | -79.59% | NA | 0.0% |
Moderna, Inc. | Buy | $40.0B | 318.83% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.8B | 166.5% | 25.9 | 30.14% |
Novo Nordisk A/s | Buy | $558.9B | 431.9% | 47.09 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.4B | 131.89% | 28.81 | 36.68% |
Institutional Holdings
Bvf Inc
16.34%Paradigm Biocapital Advisors LP
14.14%Logos Global Management LP
7.84%BlackRock Inc
5.84%Vanguard Group Inc
4.84%Cormorant Asset Management, LLC
4.39%
Corporate Announcements
Olema Pharmaceuticals Inc Earnings
Olema Pharmaceuticals Inc’s price-to-earnings ratio stands at None
Read More
Company Information
olema oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. our lead program, op-1250, a potential best-in-class complete estrogen receptor antagonist (ceran), is in development to treat estrogen receptor-positive (er+), human epidermal growth factor receptor 2-negative (her2-) breast cancer. olema recently initiated a phase 1/2 dose-escalation and expansion clinical trial of op-1250. we are supported in our mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies. for more information about the company please visit www.olema.com.
Organization | Olema Pharmaceuticals Inc |
Employees | 74 |
CEO | Dr. Sean P. Bohen M.D., Ph.D. |
Industry | Health Technology |
